The FDA approved Viridian Therapeutics’ thyroid eye disease treatment veligrotug, to be marketed as Lumvoa, setting up direct competition with Amgen’s Tepezza. The approval adds a second mechanism-backed option in a market that has become commercially significant for patients with active thyroid eye disease. Viridian’s commercialization is framed around parity pricing “in line with” Tepezza, according to the company’s CEO Steve Mahoney in the report. The approval also increases payer and prescriber choice in a condition where treatment pathways are increasingly shaped by efficacy, onset, and safety profiles. Strategically, the move compresses the competitive runway for Tepezza-based share and forces Amgen to defend differentiation beyond initial label and real-world outcomes. For Viridian, it transitions an advanced clinical asset into revenue-generating scale. The decision matters for both companies because thyroid eye disease treatment demand is ongoing, and sequencing decisions can shift quickly once additional approved options enter the marketplace.